Veeva Systems Inc. $VEEV Shares Sold by Wealthfront Advisers LLC

Wealthfront Advisers LLC decreased its holdings in Veeva Systems Inc. (NYSE:VEEV) by 7.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,191 shares of the technology company’s stock after selling 515 shares during the period. Wealthfront Advisers LLC’s holdings in Veeva Systems were worth $1,783,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of VEEV. Golden State Wealth Management LLC raised its holdings in Veeva Systems by 152.9% in the 1st quarter. Golden State Wealth Management LLC now owns 129 shares of the technology company’s stock valued at $30,000 after acquiring an additional 78 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Veeva Systems by 394.9% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,222 shares of the technology company’s stock valued at $755,000 after acquiring an additional 2,571 shares during the last quarter. Allspring Global Investments Holdings LLC boosted its position in shares of Veeva Systems by 1.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 79,249 shares of the technology company’s stock valued at $18,061,000 after acquiring an additional 1,140 shares during the last quarter. Amalgamated Bank raised its stake in Veeva Systems by 5.0% during the first quarter. Amalgamated Bank now owns 10,949 shares of the technology company’s stock worth $2,536,000 after purchasing an additional 520 shares during the period. Finally, Mather Group LLC. raised its stake in Veeva Systems by 144.3% during the first quarter. Mather Group LLC. now owns 259 shares of the technology company’s stock worth $60,000 after purchasing an additional 153 shares during the period. Institutional investors and hedge funds own 88.20% of the company’s stock.

Veeva Systems Stock Performance

Veeva Systems stock opened at $285.40 on Friday. The company’s 50 day simple moving average is $285.22 and its 200-day simple moving average is $271.73. The company has a market capitalization of $46.78 billion, a price-to-earnings ratio of 58.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.98. Veeva Systems Inc. has a 1 year low of $201.54 and a 1 year high of $310.50.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings results on Wednesday, August 27th. The technology company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.90 by ($0.64). The business had revenue of $789.08 million for the quarter, compared to analysts’ expectations of $768.49 million. Veeva Systems had a return on equity of 13.72% and a net margin of 27.29%.The firm’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $1.62 earnings per share. Veeva Systems has set its Q3 2026 guidance at 1.940-1.950 EPS. FY 2026 guidance at 7.780-7.780 EPS. Equities analysts expect that Veeva Systems Inc. will post 4.35 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Thomas D. Schwenger sold 3,350 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $300.04, for a total transaction of $1,005,134.00. Following the sale, the insider directly owned 23,773 shares of the company’s stock, valued at $7,132,850.92. This represents a 12.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eleni Nitsa Zuppas sold 6,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total transaction of $1,839,720.00. Following the sale, the insider directly owned 25,325 shares in the company, valued at approximately $7,765,151.50. The trade was a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 24,665 shares of company stock valued at $7,438,000 in the last ninety days. Company insiders own 10.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on VEEV shares. Stifel Nicolaus lifted their target price on shares of Veeva Systems from $295.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Oppenheimer reaffirmed an “outperform” rating and set a $325.00 target price on shares of Veeva Systems in a research note on Thursday, August 28th. Piper Sandler lifted their target price on shares of Veeva Systems from $325.00 to $355.00 and gave the stock an “overweight” rating in a research note on Thursday, August 28th. UBS Group lifted their target price on shares of Veeva Systems from $285.00 to $310.00 and gave the stock a “neutral” rating in a research note on Thursday, August 28th. Finally, Mizuho lifted their target price on shares of Veeva Systems from $295.00 to $325.00 and gave the stock an “outperform” rating in a research note on Friday, August 29th. Seventeen analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Veeva Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.58.

Veeva Systems Profile

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.